Use

Activating RAS mutations occur in various human malignancies, including KRAS (e.g., in pancreatic (~80–90%) and colorectal (~30–60%) carcinomas), HRAS (non‑melanoma skin cancers ~30–50%), and NRAS (hematopoietic neoplasias ~18–30%). KRAS mutations generally signify adverse prognosis and resistance to receptor tyrosine kinase‑directed therapies, including EGFR inhibitors. Specifically, KRAS G12C has been associated with response to targeted KRAS G12C inhibitors and is a biomarker in NSCLC (~13% prevalence, comprising ~44% of KRAS variants). The assay is CLIA‑validated for clinical use but has not been cleared or approved by the FDA.